| Abstrakt: |
Breast cancer has become the most common type of cancer worldwide since 2021. Despite recent advances in therapies, many patients with breast cancer experience tumor relapse and drug resistance, which are believed to attribute to breast cancer stem cells (CSCs), a small population of cells within breast cancer. Therefore, eradicating breast CSCs represents a promising therapeutical strategy to prevent cancer reoccurrence and drug resistance. Current studies have shown that breast CSCs arise from normal mammary stem cells/progenitor cells or differentiated mammary cells. Multiple key signaling pathways have been discovered and implicated in breast CSCs' self-renewal and differentiation, including Wnt/ß-catenin signaling. In this article, I review the recent progress in breast CSC's biological studies and therapeutics by targeting breast CSCs' biomarkers and the Wnt/ß-catenin signaling pathway. [ABSTRACT FROM AUTHOR] |
